Irma Egoavil – Country Manager, Celgene Mexico
Celgene is committed to improving the lives of patients through innovation. The country manager of the recently opened Mexico affiliate explains the importance of having a direct presence in the…
Celgene is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, and ISTODAX. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs® compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to our leading oral anti-inflammatory agents and cellular therapies. We believe our commercial stage products and the depth of our product pipeline, provide the catalysts for future growth.
Contact details
Celgene México
Juan Salvador Agraz 65, Piso 17,
Colonia Lomas de Santa Fe.
C.P. 05300. México, D.F.
MEXICO
Tel: +52 (55) 41236700
Website: www.celgene.com
Celgene is committed to improving the lives of patients through innovation. The country manager of the recently opened Mexico affiliate explains the importance of having a direct presence in the…
Below is a selection of top recent news from Mexican pharma and healthcare, including the healthcare reforms president Andres Manuel Lopez Obrador is prioritising, latest news on the INSABI program,…
Between 2015 and 2017 PharmaBoardroom met with pharma country managers in Mexico who spoke about the challenges and opportunities present in the Mexican market. Since then, these five stakeholders have…
The United States Trade Representative Office has been engaging with a number of countries, including Mexico, to address concerns related to IP protection and enforcement and market access barriers for…
What traits, competencies and drivers do you need to be a successful pharma country manager in today’s dynamic Mexican pharma market? Jose Guerrero and Male Mejido from the Mexico office…
Cristobal Thompson of the AMIIF examines the steps forward that Mexican pharma has made in countering corruption, the areas in which urgent improvement is still needed, and outlines the three…
Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). In this article, he introduces us to an exciting new youth program set up to improve…
Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health…
David Peña Castillo, president and founder of the Mexican Federation of Rare Diseases (FEMEXER), addresses the problem of patients deserting therapies. In Mexico, approximately 15 percent of patients treated…
Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health…
Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health…
Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving…
David Peña Castillo is the President and founder of The Mexican Federation of Rare Diseases (FEMEXER). Here he discusses what makes a patients association. When we find a way to…
See our Cookie Privacy Policy Here
